Expand EXEL Menu
EXEL MENU

EXEL Latest Press Releases

-- January 11, 2026 --

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 Business Wire 4:00 PM

-- January 7, 2026 --

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Business Wire 8:00 AM

-- January 6, 2026 --

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Business Wire 4:05 PM

-- December 12, 2025 --

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era Globe Newswire 10:31 AM

-- December 3, 2025 --

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 Business Wire 4:05 PM

-- November 6, 2025 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November Business Wire 4:05 PM

-- November 4, 2025 --

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- October 28, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:11 AM

-- October 23, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:00 AM

-- October 21, 2025 --

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Business Wire 4:05 PM
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners PRNewswire 8:05 AM
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress Globe Newswire 7:00 AM

-- October 20, 2025 --

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet Business Wire 2:30 AM

-- October 18, 2025 --

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 Business Wire 3:00 AM

-- September 14, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL Globe Newswire 10:00 AM

-- September 13, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:00 AM

-- September 10, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL Globe Newswire 2:50 PM

-- September 8, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 3:30 PM

-- September 6, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL Globe Newswire 10:00 AM

-- September 3, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:00 AM

-- September 2, 2025 --

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm Business Wire 4:49 PM

-- August 29, 2025 --

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development Business Wire 5:47 PM

-- August 27, 2025 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Business Wire 4:05 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:00 AM

-- August 22, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL PRNewswire 10:00 AM
Market Data Delayed 15 Minutes